Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus | RheumNow
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).